OKYO Pharma Ltd
corporate_fare Company Profile
OKYO Pharma Ltd (NASDAQ:OKYO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for OKYO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for OKYO spans 6-K, 424B5, F-3.
Recent high-impact activity:
- OKYO Pharma Enrolls First Patients in Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal Pain
- OKYO Pharma Files Annual Report, $20.6M Cash to Fund Phase 3 NEPTUNE Trial
- FDA Validates Urcosimod Phase 3 Path for Neuropathic Corneal Pain, Eyes Single-Trial Registration
- FDA Greenlights OKYO Pharma's Urcosimod for Pivotal Phase 3 Trial in Neuropathic Corneal Pain
- OKYO Pharma Expands Scientific Advisory Board with Key Ophthalmology Expert
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 45,609 shares in OKYO as of the October 30, 2026 settlement, a 40.5% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 44.7% of OKYO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
OKYO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.